EU regulators recommend against renewing approval for GSK's Blenrep
https://seekingalpha.com/news/4046976-eu-regulators-recommend-against-renewing-approval-for-gsks-blenrep?source=feed_sector_healthcare
Dec 15, 2023 - EU regulators have reportedly declined to recommend renewing conditional approval for GSK’s (GSK) blood cancer drug Blenrep. According to Reuters, a European Me
0
GSK looking to boost pipeline with respiratory, auto-immune deals - report
https://seekingalpha.com/news/4050326-gsk-looking-to-boost-pipeline-with-respiratory-auto-immune-deals-report?source=feed_sector_healthcare
Dec 26, 2023 - GSK plans to strengthen its drug portfolio through acquisitions in respiratory and auto-immune areas, with a focus on deals worth around $2 billion over the...
0
GSK, Pfizer-backed ViiV gets FDA okay for HIV drug for adolescents
https://seekingalpha.com/news/4087977-gsk-pfizer-backed-viiv-gets-fda-okay-for-hiv-drug-for-adolescents?source=feed_sector_healthcare
Apr 08, 2024 - ViiV Healthcare said it has received FDA approval for its drug Dovato in the treatment of HIV-1 infection in adolescents 12 years old and older. Read more here.
0
GSK shingles vaccine shown 82% effective 11 years after vaccination
https://seekingalpha.com/news/4090624-gsk-shingles-vaccine-shown-highly-effective-11-years-after-vaccination?source=feed_sector_healthcare
Apr 17, 2024 - GSK (GSK) said studies showed that its top-selling shingles vaccine, Shingrix, had an 82% efficacy rate 11 years after vaccination in people aged 50 and older. Read more here.
0
GSK Jemperli gets Europe clearance as frontline endometrial cancer therapy
https://seekingalpha.com/news/4045127-gsk-jemperli-gets-europe-clearance-as-frontline-endometrial-cancer-therapy?source=feed_sector_healthcare
Dec 11, 2023 - GSK receives European approval for Jemperli as a frontline immuno-oncology treatment for endometrial cancer, expanding treatment options for patients.
0
Week In Review: Two Billion-Dollar Deals As 2023 Nears End - Hansoh-GSK; Nona-Pfizer
https://seekingalpha.com/article/4659466-week-in-review-two-billion-dollar-deals-2023-nears-end-hansoh-gsk-nona-pfizer?source=feed_all_articles
Dec 24, 2023 - GSK acquired ex-Greater China rights to a second ADC from Hansoh Pharma in a $1.7 billion agreement. Boston's Nona Biosciences out-licensed global rights for its MSLN-targeted ADC to Pfizer.
0
Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
https://www.cnbc.com/2024/01/14/cancer-drugs-renewed-interest-in-adcs-will-continue-in-2024.html
Jan 14, 2024 - The JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer drugs.
0
GSK to sell 3.2% stake in spinoff Haleon: report
https://seekingalpha.com/news/4055337-gsk-to-sell-stake-in-spinoff-haleon-report?source=feed_sector_healthcare
Jan 16, 2024 - GSK (GSK) reportedly plans to sell a 3.2% stake in consumer healthcare products company Haleon (HLN), which it spun off in 2019. Read more here.
0
Watch GSK amid evidence hearing on Zantac litigation
https://seekingalpha.com/news/4057520-watch-gsk-amid-hearing-on-zantac-litigation?source=feed_sector_healthcare
Jan 23, 2024 - Investors should watch GSK amid a pre-trial hearing over litigation related to the heartburn medication Zantac, which could result in billions of...
0
GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost
https://www.cnbc.com/2024/01/31/gsk-posts-blowout-rsv-vaccine-sales-raises-outlook.html
Jan 31, 2024 - The RSV shot, called Arexvy, booked £1.2 billion, or $1.5 billion, in sales after only being on the market for roughly half a year.
0
Page 1>